Comparative Pharmacology
Head-to-head clinical analysis: HYDROCHLOROTHIAZIDE INTENSOL versus TRICHLORMETHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCHLOROTHIAZIDE INTENSOL versus TRICHLORMETHIAZIDE.
HYDROCHLOROTHIAZIDE INTENSOL vs TRICHLORMETHIAZIDE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and chloride reabsorption and increasing water excretion.
Inhibits sodium-chloride symporter in distal convoluted tubule, increasing excretion of sodium, chloride, and water.
HypertensionEdema associated with congestive heart failure, cirrhosis, or renal disease
HypertensionEdema associated with congestive heart failure, cirrhosis, renal disease, or corticosteroid/estrogen therapy
25-100 mg orally once daily or in divided doses. Titrate based on response; maximum 200 mg/day.
2-4 mg orally once daily; maximum 4 mg/day.
None Documented
None Documented
Terminal half-life 6–15 hours (mean ~10 hours); prolonged in renal impairment (creatinine clearance <30 mL/min) and elderly.
Terminal elimination half-life is approximately 2-6 hours (average 3.5 h); clinical context: short half-life necessitates once or twice daily dosing for sustained diuresis.
Not extensively metabolized; eliminated primarily unchanged by renal tubular secretion
Primarily renal excretion of unchanged drug; minimal hepatic metabolism.
Primarily renal (≥95% as unchanged drug); negligible biliary/fecal elimination (<5%).
Primarily renal (tubular secretion); ~70% excreted unchanged in urine; minor biliary/fecal (<10% total).
~68% bound, primarily to albumin.
Highly protein bound: ~99% bound to albumin and other plasma proteins.
Vd 0.8–1.6 L/kg (mean ~1.2 L/kg); distributes into extracellular fluid and crosses placenta.
Volume of distribution is approximately 1.5-2.5 L/kg; clinical meaning: indicates extensive tissue binding and limited central compartment distribution.
Oral bioavailability ~65–75% (range 50–80%); food may slightly enhance absorption.
Oral bioavailability is approximately 70-85% (well absorbed); no other relevant routes.
GFR 30-50 mL/min: reduce dose by 50% or administer every 24-48 hours. GFR <30 mL/min: generally ineffective, consider alternative.
eGFR 30-59 mL/min: reduce dose by 50%; eGFR <30 mL/min: use alternative agent or maximum 2 mg/day.
Child-Pugh A: no adjustment. Child-Pugh B or C: use with caution; consider dose reduction due to risk of electrolyte disturbances and hepatic encephalopathy.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
1-2 mg/kg/day orally once daily or in divided doses. Maximum 100 mg/day. Not recommended for infants <2 years.
0.02-0.04 mg/kg orally once daily; maximum 0.2 mg/kg/day.
Start at 12.5-25 mg orally once daily; titrate slowly. Monitor electrolyte levels and renal function. Increased risk of hyponatremia and hypokalemia.
Start at 2 mg orally once daily; titrate cautiously due to increased risk of electrolyte imbalance and hypotension.
None
No black box warning.
["Hypokalemia","Hyponatremia","Hyperuricemia","Acute myopia/secondary angle-closure glaucoma","Sulfonamide allergy cross-reactivity"]
["Hypokalemia","Hyponatremia","Hypomagnesemia","Hypercalcemia","Dehydration","Azotemia","Sulfonamide allergy cross-reactivity","Photosensitivity","Exacerbation of systemic lupus erythematosus"]
["Anuria","Hypersensitivity to sulfonamide-derived drugs"]
["Anuria","Hypersensitivity to sulfonamides or thiazide diuretics"]
Data Pending Review
Data Pending Review
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, tomatoes, leafy greens) unless directed by a physician, as HCTZ can cause hypokalemia. However, routine potassium supplementation is not recommended unless hypokalemia develops. Decrease dietary sodium intake to enhance antihypertensive effect. Grapefruit juice does not interact significantly with HCTZ. Alcohol may potentiate orthostatic hypotension.
Avoid excessive intake of high-potassium foods (e.g., bananas, oranges, potatoes) unless directed otherwise. Limit sodium intake to enhance antihypertensive effect. Grapefruit juice may increase drug absorption; avoid large amounts.
First trimester: Limited data; thiazide diuretics are generally avoided due to potential placental hypoperfusion. Second/third trimester: May cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Avoid for treatment of gestational hypertension unless other options are contraindicated.
First trimester: Limited data; thiazides are generally avoided due to potential placental hypoperfusion and electrolyte disturbances. Second and third trimesters: Use may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte imbalances. Avoid for treatment of gestational hypertension as it reduces plasma volume and may impair uteroplacental perfusion.
Hydrochlorothiazide is excreted in breast milk in low concentrations; M/P ratio unknown. May suppress lactation and cause neonatal electrolyte disturbances. Use with caution, especially in newborns or preterm infants.
Excreted into human milk in small amounts; M/P ratio unknown. May suppress lactation. Caution in breastfeeding due to risk of neonatal electrolyte disturbances and thiazide effects.
Dose adjustments are not typically recommended based on pharmacokinetic changes alone. Use lowest effective dose if necessary. Caution with volume depletion and electrolyte disturbances. Reduce dose or discontinue if hypotension or electrolyte abnormalities occur.
No specific dose adjustment recommended; however, increased volume of distribution and renal clearance in pregnancy may necessitate dose increases. Use lowest effective dose and shorten duration. Avoid in preeclampsia due to volume depletion risk.
Category A/B
Category C
Hydrochlorothiazide (HCTZ) Intensol is a concentrated oral solution (100 mg/mL) used for patients who have difficulty swallowing tablets or require flexible dosing. Monitor serum electrolytes (especially potassium, sodium, magnesium) and renal function before and during therapy. HCTZ may cause acute angle-closure glaucoma; advise patients to report eye pain or blurred vision. It can precipitate gout by increasing serum uric acid. Avoid use in patients with anuria or hypersensitivity to sulfonamides. Concomitant use with lithium may increase lithium levels; monitor closely. NSAIDs can reduce the antihypertensive effect. Onset of diuresis occurs within 2 hours, peak at 4 hours, duration 6-12 hours. Use caution in hepatic impairment as electrolyte changes may precipitate hepatic encephalopathy.
Monitor serum potassium closely due to hypokalemia risk; use cautiously in patients with hepatic impairment or cirrhosis (can precipitate hepatic encephalopathy). May exacerbate gout; check uric acid levels. Onset of action is within 2 hours, peak at 4-6 hours, duration 12-24 hours. Use with caution in patients with sulfonamide allergy (cross-sensitivity).
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.Measure the dose carefully using the provided dropper; mix with water, juice, or a soft food like applesauce before taking.Avoid prolonged sun exposure and use sunscreen as HCTZ increases risk of photosensitivity and skin cancer.Report symptoms of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, excessive thirst, or confusion.Do not stop taking the medication abruptly without consulting your doctor; it is used to control blood pressure or edema.Inform your doctor of all other medications, especially lithium, NSAIDs, other blood pressure drugs, and steroids.Limit alcohol intake as it may worsen dizziness or hypotension.If you have diabetes, monitor blood sugar more frequently as HCTZ may increase blood glucose levels.
Take exactly as prescribed, usually once daily in the morning to avoid nighttime urination.Avoid potassium supplements or salt substitutes without consulting your doctor.Report symptoms of low potassium (muscle cramps, weakness, irregular heartbeat) or high blood sugar (increased thirst, frequent urination).May cause dizziness or lightheadedness; rise slowly from sitting or lying down.Limit alcohol intake as it may enhance blood pressure lowering effects.